Dustin A. Cobb, Ok‐Kyung Kim, Lucy Golden‐Mason, Hugo R. Rosen, Young S. Hahn – 27 July 2017 – Hepatitis C virus (HCV) is a global health concern that can cause severe liver disease, such as cirrhosis and hepatocellular carcinoma. Control of HCV requires vigorous T‐cell responses, yet CD4+ T cells in chronic HCV patients are dysfunctional. T follicular regulatory (Tfr) cells are a subset of regulatory T cells that suppress T follicular helper (Tfh) cells and the generation of high affinity antibody‐producing B cells.

Xiaoying Liu, Richard M. Green – 27 July 2017

Lisa I. Backus, Pamela S. Belperio, Troy A. Shahoumian, Larry A. Mole – 27 July 2017 – The impact of sustained virologic response (SVR) on mortality after direct‐acting antiviral treatment is not well documented. This study evaluated the impact of direct‐acting antiviral–induced SVR on all‐cause mortality and on incident hepatocellular carcinoma (HCC) in 15,059 hepatitis C virus–infected patients with advanced liver disease defined by a FIB‐4 >3.25. Overall, 1,067 patients did not achieve SVR (no SVR) and 13,992 patients achieved SVR.

Xiaoying Liu, Richard M. Green – 27 July 2017

Sandeep Singh Sidhu, Barjesh Chander Sharma, Omesh Goyal, Harsh Kishore, Navpreet Kaur – 27 July 2017 – High‐quality data on the efficacy of L‐ornithine L‐aspartate (LOLA) in patients with cirrhosis and bouts of overt hepatic encephalopathy (OHE) are missing. We evaluated the efficacy of intravenous LOLA in the reversal of bouts of OHE in patients with cirrhosis. In this prospective, double‐blind, randomized, placebo‐controlled trial conducted at two tertiary care institutes in India, 370 patients with cirrhosis and bouts of OHE were screened.

Masashi Hirooka, Yohei Koizumi, Teruki Miyake, Takao Watanabe, Osamu Yoshida, Yoshio Tokumoto, Atsushi Yukimoto, Yoshiko Nakamura, Yusuke Imai, Masanori Abe, Yoichi Hiasa – 27 July 2017 – A change in hepatic blood flow caused by the hepatic arterial buffer response (HABR) occurs as fatty liver disease progress. The aim of this longitudinal cohort study was to investigate whether fatty liver with the HABR induces metabolic disorders. In 2009 and 2010, 494 (89.5%) participants were enrolled. The median follow‐up duration was 5.0 (interquartile range, 3.9‐6.0) years.

Gaiyun Li, Yuanfei Zhu, Dianhui Shao, Hao Chang, Xiaoming Zhang, Dongming Zhou, Yueqiu Gao, Ke Lan, Qiang Deng – 27 July 2017 – Covalently closed circular DNA of hepatitis B virus (HBV) is critical for viral persistence in vivo. We recently reported a technique involving recombinant covalently closed circular DNA (rcccDNA) of HBV by site‐specific DNA recombination. Using hydrodynamic injection, rcccDNA induces a temporarily prolonged HBV antigenemia in immunocompetent mice, similar to acute resolving HBV infection.

Michael M.C. Lai, Wen‐Chi Su – 27 July 2017

Diego Moya‐Nájera, Ángel Moya‐Herraiz, Luis Compte‐Torrero, David Hervás, Sebastien Borreani, Joaquin Calatayud, Marina Berenguer, Juan C. Colado – 27 July 2017 – Although currently moderate and high intensity concurrent physical exercise is prescribed in populations with special needs due to its greater effect on physical condition and health‐related quality of life (HRQOL), there are no data in the liver transplantation (LT) setting.

Sandeep Singh Sidhu, Barjesh Chander Sharma, Omesh Goyal, Harsh Kishore, Navpreet Kaur – 27 July 2017 – High‐quality data on the efficacy of L‐ornithine L‐aspartate (LOLA) in patients with cirrhosis and bouts of overt hepatic encephalopathy (OHE) are missing. We evaluated the efficacy of intravenous LOLA in the reversal of bouts of OHE in patients with cirrhosis. In this prospective, double‐blind, randomized, placebo‐controlled trial conducted at two tertiary care institutes in India, 370 patients with cirrhosis and bouts of OHE were screened.